Sugi Predict

Sugi Predict / Compounds / SCHEMBL397839

SCHEMBL397839

SCHEMBL397839

Cc1ccccc1C(=O)NC1(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.51
▸ NPC1 O15118 5/20 0.49
▸ RAB9A P51151 5/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ P2RX7 Q99572 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ TYK2 P29597 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21652024 0.88 P2RX7 (0.57) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL27847002 0.85 HPGD (0.47) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL20068953 0.84 P2RX7 (0.47) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL30848613 0.78 FAAH (0.61) HPGDNPC1RAB9ASMN1; SMN2GLA
SCHEMBL13193074 0.78 HPGD (0.47) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL10279699 0.78 NPC1 (0.48) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL30848469 0.77 HPGD (0.46) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL13164041 0.77 PYGL (0.54) HPGDPOLB
SCHEMBL31079661 0.77 HPGD (0.46) HPGDNPC1RAB9ASMN1; SMN2P2RX7
SCHEMBL10279697 0.77 CTSL (0.48) HPGDNPC1RAB9ASMN1; SMN2P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118043327-A FGFR inhibitors and methods of use thereof 思康睿奇(上海)药业有限公司 2024-05-14 — — CN claimed
CN-103649087-A Substituted imidazopyridines and intermediates thereof BAYER IP GMBH 2014-03-19 — — CN claimed
EP-2694500-A1 SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF Bayer Pharma Aktiengesellschaft (DE) 2014-02-12 — — EP claimed
WO-2014020041-A1 COMBINATIONS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-02-06 — — WO claimed
WO-2012136531-A1 SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-11 — — WO claimed
CN-118043327-A FGFR inhibitors and methods of use thereof 思康睿奇(上海)药业有限公司 2024-05-14 — — CN disclosed
US-20170305912-A1 PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-26 — — US disclosed
US-20170305912-A1 PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-26 — — US disclosed
US-9512126-B2 Substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-12-06 — — US disclosed
US-9512126-B2 Substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-12-06 — — US disclosed
EP-2825540-B1 SUBSTITUTED IMIDAZOPYRIDAZINES BAYER IP GMBH (DE) 2016-09-14 — — EP disclosed
WO-2016034507-A1 A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-10 — — WO disclosed
US-20140255392-A1 SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-11 — — US disclosed
CN-103649087-A Substituted imidazopyridines and intermediates thereof BAYER IP GMBH 2014-03-19 — — CN disclosed
WO-2014020041-A1 COMBINATIONS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-02-06 — — WO disclosed
US-8455495-B2 Pyridazino-pyridinone compounds and methods of use AMGEN INC. (US) 2013-06-04 — — US disclosed
WO-2012136531-A1 SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-11 — — WO disclosed
WO-2012032031-A1 SUBSTITUTED IMIDAZOPYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-15 — — WO disclosed
US-8101612-B2 N-3-isoxazolyl-4-methyl-3-(1-((1-methylethyl)oxy)-6-phthalazinyl)benzamide; p38 kinase inhibitor; antiinflammatory, analgesic agent; rheumatoid arthritis, osteoporosis, leukemia, psoriasis, Crohn's disease, rhinitis, ulcerative colitis, dermatitis, asthma, Alzheimer's disease, type I and II diabetes AMGEN INC. (US) 2012-01-24 — — US disclosed
US-20080119468-A1 Phthalazine, aza-and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2008-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119468-A1 Phthalazine, aza-and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 HPGD 2348/4885NPC1 4272/4885RAB9A 3386/4885
US-20140255392-A1 SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF FLT4, KDR, VEGFA HPGD 166/4885NPC1 2593/4885RAB9A 2032/4885
US-20170305912-A1 PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES TTBK1, TTK, TTBK2 HPGD 4762/4885NPC1 2377/4885RAB9A 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.